1. Home
  2. MRLN vs CGEM Comparison

MRLN vs CGEM Comparison

Compare MRLN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MRLN

Merlin Inc. Common Stock

N/A

Current Price

$8.10

Market Cap

915.1M

Sector

Technology

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.35

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRLN
CGEM
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
915.1M
904.7M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
MRLN
CGEM
Price
$8.10
$16.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$25.00
$30.13
AVG Volume (30 Days)
1.5M
956.5K
Earning Date
10-28-2021
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.78
$5.68
52 Week High
$17.00
$16.74

Technical Indicators

Market Signals
Indicator
MRLN
CGEM
Relative Strength Index (RSI) 47.80 62.01
Support Level $6.07 $11.92
Resistance Level $17.00 N/A
Average True Range (ATR) 0.85 1.03
MACD 0.19 0.08
Stochastic Oscillator 76.66 89.05

Price Performance

Historical Comparison
MRLN
CGEM

About MRLN Merlin Inc. Common Stock

Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: